Oral dysplasia: Biomarkers, treatment, and follow-up

Current Oncology Reports

Volumn 13, Issue 2, 2011, Pages 145-152

  Nankivell, Paul ^a   Mehanna, Hisham ^a  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

Author keywords

Biomarkers; Dysplasia; Follow up; Management; Oral; Pre cancer; Treatment

Indexed keywords

BETA CAROTENE; BIOLOGICAL MARKER; BLEOMYCIN; BONE SIALOPROTEIN; CATHEPSIN L; CELECOXIB; CETUXIMAB; CHECKPOINT KINASE 2; CYCLIN A1; CYTOKERATIN 4; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FENRETINIDE; GELATINASE A; GEMININ; INTERSTITIAL COLLAGENASE; KI 67 ANTIGEN; MINICHROMOSOME MAINTENANCE PROTEIN 2; OSTEOPONTIN; PLACEBO; PODOPLANIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN P16; PROTEIN P53; PROTEIN P73; PROTEIN TYROSINE KINASE INHIBITOR; RETINOL; TEMOPORFIN; UNINDEXED DRUG;

CANCER EPIDEMIOLOGY; CHEMOPROPHYLAXIS; CONSERVATIVE TREATMENT; CRYOSURGERY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; GENE EXPRESSION REGULATION; HEAD AND NECK CANCER; HUMAN; LASER; LASER SURGERY; LEUKOPENIA; LEUKOPLAKIA; LIFESTYLE MODIFICATION; MOUTH CANCER; MOUTH MALFORMATION; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR;

DISEASE PROGRESSION; HUMANS; MOUTH DISEASES; MOUTH MUCOSA; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL;

EID: 79955830292     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-010-0150-z     Document Type: Review

References (59)

1. Warnakulasuriya S, Johnson NW, Van Der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. Journal of Oral Pathology & Medicine. 2007;36 (10):575-80. (Pubitemid 47609807)
2. Organization GWH. World Health Organization. Report of a meeting of inves- tigators on the histological definition of precancerous lesions. . 1973 Can ?731.
3. Thomson P. Field change and oral cancer: new evidence for widespread carcinogenesis? International journal of oral and maxillofacial surgery. [10.1054/ijom.2002.0220]. 2002;31 (12190131):262-6. This paper demonstrated that dysplastic change can occur in apparently normal-looking mucosa at a site distant from the obvious dysplastic lesion.
4. van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; present concepts of management. Oral oncology. [10.1016/j.oraloncology.2010.02.016]. 2010;46 (20308005):423-5.
5. Petti S. Pooled estimate of world leukoplakia prevalence: a systematic review. Oral Oncology. 2003;39(13679200):770-80. (Pubitemid 38373461)
6. Online I. ISD Online, 2010 Cancer Incidence and Mortality data, 2008.
7. Agency NISaR. Northern Ireland Statistics and Research Agency 2010 Northern Ireland Mortality data, 2008.
8. Statistics OfN. Office for National Statistics, 2010 Mortality Statistics: Cause, 2008.
9. Lodi G, Sardella A, Bez C, Demarosi F, Carrassi A. Interventions for treating oral leukoplakia. Cochrane database of systematic reviews (Online). [10.1002/14651858.CD001829. pub3]. 2006(17054142):CD001829. This review demonstrated the lack of evidence that any treatments prevent malignant transformation of oral leukoplakia.
10. Mehanna HM, Rattay T, Smith J, McConkey CC. Treatment and follow-up of oral dysplasia-a systematic review and metaanalysis. Head Neck. 2009 Dec;31(12):1600-9. This is a thorough systematic review of the highest-quality evidence available on the treatment and follow-up of oral dysplasia.
11. Thomson P, Wylie J. Interventional laser surgery: an effective surgical and diagnostic tool in oral precancer management. International journal of oral and maxillofacial surgery. [10.1054/ijom.2001.0189]. 2002;31(12102411):145-53.
12. Napier SS, Speight PM. Natural history of potentially malignant oral lesions and conditions: an overview of the literature. J Oral Pathol Med. 2008 Jan;37(1):1-10. This excellent review on the natural history of leukoplakia is part of a series of publications to come from a workshop coordinated by the WHO Collaborating Center for Oral Cancer and Precancer.
13. Vladimirov BS, Schiodt M. The effect of quitting smoking on the risk of unfavorable events after surgical treatment of oral potentially malignant lesions. Int J Oral Maxillofac Surg. 2009 Nov;38(11):1188-93.
14. Epstein JB, Wong FL, Millner A, Le ND. Topical bleomycin treatment of oral leukoplakia: a randomized double-blind clinical trial. Head Neck. 1994 Nov-Dec;16(6):539-44.
15. Sankaranarayanan R, Mathew B, Varghese C, Sudhakaran PR, Menon V, Jayadeep A, et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncol. 1997 Jul;33(4):231-6.
16. Lippman SM, Lee JJ, Martin JW, El-Naggar AK, Xu X, Shin DM, et al. Fenretinide activity in retinoid-resistant oral leukoplakia. Clinical cancer research : an official journal of the American Association for Cancer Research. [10.1158/1078-0432.CCR-05-2636]. 2006;12(16707609):3109-14. (Pubitemid 43837358)
17. Chiesa F, Tradati N, Grigolato R, Boracchi P, Biganzoli E, Crose N, et al. Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results. International journal of cancer Journal international du cancer. [10.1002/ijc.20923]. 2005;115(15700313):625-9. (Pubitemid 40656722)
18. William WN, Lee JJ, Lippman SM, Martin JW, Chakravarti N, Tran HT, et al. High-dose fenretinide in oral leukoplakia. Cancer prevention research (Philadelphia, Pa). [10.1158/1940-6207. CAPR-08-0100]. 2009;2(19139014):22-6.
19. Renkonen J, Wolff H, Paavonen T. Expression of cyclooxygenase- 2 in human tongue carcinoma and its precursor lesions. Virchows Arch. 2002 Jun;440(6):594-7. (Pubitemid 34809690)
20. Shaheen NJ, Straus WL, Sandler RS. Chemoprevention of gastrointestinal malignancies with nonsteroidal antiinflammatory drugs. Cancer. 2002 Feb 15;94(4):950-63. (Pubitemid 34150849)
21. Papadimitrakopoulou VA, William WN, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical cancer research : an official journal of the American Association for Cancer Research. [10.1158/1078-0432.CCR-07-4024]. 2008;14 (18381950):2095-101. (Pubitemid 351551121)
22. Wirth LJ, Krane JF, Li Y, Othus M, Moran AE, Dorfman DM, et al. A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. Cancer prevention research (Philadelphia, Pa). [10.1158/1940-6207.CAPR-07-0003]. 2008;1(19138978):339-48.
23. Mulshine JL, Atkinson JC, Greer RO, Papadimitrakopoulou VA, Van Waes C, Rudy S, et al. Randomized, double-blind, placebocontrolled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res. 2004 Mar 1;10(5):1565-73. (Pubitemid 38435544)
24. Zhang S, Li Y, Li L, Zhang Y, Gao N, Zhang Z, et al. Phase I study of repeated intraepithelial delivery of adenoviral p53 in patients with dysplastic oral leukoplakia. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons. [10.1016/j.joms.2008.06.079]. 2009;67(19375021):1074-82.
25. Rigual NR, Thankappan K, Cooper M, Sullivan MA, Dougherty T, Popat SR, et al. Photodynamic therapy for head and neck dysplasia and cancer. Archives of otolaryngology-head & neck surgery. [10.1001/archoto.2009.98]. 2009;135(19687399):784-8.
26. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res. 1996 Jun;56(11):2488-92. (Pubitemid 26170679)
27. Barnes L EJ, Reichart P, Sidransky D. World Health Organization classification of tumours. Pathology and genetics of tumours of the head and neck: IARC Press: Lyon; 2005.
28. Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E. Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. [10.1111/j.1600-0714.2007.00584.x]. 2008;37 (18251935):127-33. (Pubitemid 351178405)
29. Fleskens S, Slootweg P. Grading systems in head and neck dysplasia: their prognostic value, weaknesses and utility. Head Neck Oncol. 2009;1(1):11.
30. Smith J, Rattay T, McConkey C, Helliwell T, Mehanna H. Biomarkers in dysplasia of the oral cavity: a systematic review. Oral Oncol. 2009 Aug;45(8):647-53.
31. Lo Muzio L, Pannone G, Leonardi R, Staibano S, Mignogna MD, De Rosa G, et al. Survivin, a potential early predictor of tumor progression in the oral mucosa. J Dent Res. 2003 Nov;82 (11):923-8. (Pubitemid 41756876)
32. Jordan RC, Macabeo-Ong M, Shiboski CH, Dekker N, Ginzinger DG, Wong DT, et al. Overexpression of matrix metalloproteinase- 1 and -9 mRNA is associated with progression of oral dysplasia to cancer. Clin Cancer Res. 2004 Oct 1;10(19):6460-5. (Pubitemid 39346541)
33. Yoon AJ, Shen J, Santella RM, Zegarelli DJ, Chen R, Weinstein IB. Activated checkpoint kinase 2 expression and risk for oral squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2768-72. (Pubitemid 351196335)
34. Hall GL, Shaw RJ, Field EA, Rogers SN, Sutton DN, Woolgar JA, et al. p16 Promoter methylation is a potential predictor of malignant transformation in oral epithelial dysplasia. Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2174-9.
35. Torres-Rendon A, Roy S, Craig GT, Speight PM. Expression of Mcm2, geminin and Ki67 in normal oral mucosa, oral epithelial dysplasias and their corresponding squamous-cell carcinomas. Br J Cancer. 2009 Apr 7;100(7):1128-34
36. Taoudi Benchekroun M, Saintigny P, Thomas SM, El-Naggar AK, Papadimitrakopoulou V, Ren H, et al. Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prevention Research. [10.1158/1940-6207.CAPR- 09-0163]. 2010;3(20570883):800-9.
37. Saintigny P, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, et al. DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia. Clin Cancer Res. 2009 Oct 1;15(19):6284-91.
38. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, et al. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. [10.1200/JCO.2007.13.4072]. 2008;26(18202409):354- 60.
39. Ogbureke KU, Abdelsayed RA, Kushner H, Li L, Fisher LW. Two members of the SIBLING family of proteins, DSPP and BSP, may predict the transition of oral epithelial dysplasia to oral squamous cell carcinoma. Cancer. 2010 Apr 1;116(7):1709-17.
40. Rosin MP, Cheng X, Poh C, Lam WL, Huang Y, Lovas J, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000;6 (10690511):357-62. (Pubitemid 30111451)
41. Zhou X, Jordan RC, Li Y, Huang BL, Wong DT. Frequent allelic imbalances at 8p and 11q22 in oral and oropharyngeal epithelial dysplastic lesions. Cancer Genet Cytogenet. 2005 Aug;161(1):86-9. (Pubitemid 41096057)
42. Partridge M, Emilion G, Pateromichelakis S, A'Hern R, Phillips E, Langdon J. Allelic imbalance at chromosomal loci implicated in the pathogenesis of oral precancer, cumulative loss and its relationship with progression to cancer. Oral Oncol. 1998 Mar;34(2):77-83. (Pubitemid 28207005)
43. Hogmo A, Lindskog S, Lindholm J, Kuylenstierna R, Auer G, Munck-Wikland E. Preneoplastic oral lesions: the clinical value of image cytometry DNA analysis, p53 and p21/WAF1 expression. Anticancer Res. 1998 Sep-Oct;18(5B):3645- 50. (Pubitemid 28564241)
44. Torres-Rendon A, Stewart R, Craig GT, Wells M, Speight PM. DNA ploidy analysis by image cytometry helps to identify oral epithelial dysplasias with a high risk of malignant progression. Oral Oncol. 2009 Jun;45(6):468-73.
45. Tsui IF, Poh C, Garnis C, Rosin M, Zhang L, Lam W. Multiple pathways in the FGF signaling network are frequently deregulated by gene amplification in oral dysplasias. International journal of cancer Journal international du cancer. [10.1002/ijc.24611]. 2009;125(19623652):2219-28.
46. Sundvall M, Karrila A, Nordberg J, Grenman R, Elenius K. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma. Expert Opin Emerg Drugs. 2010 Jun;15(2):185-201.
47. Cruz IB, Snijders PJ, Meijer CJ, Braakhuis BJ, Snow GB, Walboomers JM, et al. p53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma. J Pathol. 1998 Apr;184(4):360-8.
48. Cruz I, Napier SS, van der Waal I, Snijders PJ, Walboomers JM, Lamey PJ, et al. Suprabasal p53 immunoexpression is strongly associated with high grade dysplasia and risk for malignant transformation in potentially malignant oral lesions from Northern Ireland. J Clin Pathol. 2002 Feb;55(2):98-104. (Pubitemid 34123908)
49. Regezi JA, Zarbo RJ, Regev E, Pisanty S, Silverman S, Gazit D. p53 protein expression in sequential biopsies of oral dysplasias and in situ carcinomas. J Oral Pathol Med. 1995 Jan;24(1):18-22.
50. Rich AM, Kerdpon D, Reade PC. p53 expression in oral precancer and cancer. Aust Dent J. 1999 Jun;44(2):103-5.
51. Shahnavaz SA, Regezi JA, Bradley G, Dube ID, Jordan RC. p53 gene mutations in sequential oral epithelial dysplasias and squamous cell carcinomas. J Pathol. 2000 Mar;190(4):417-22. (Pubitemid 30163580)
52. Nankivell P WM, McConkey C, Paleri V, Mehanna H. Biomarkers in laryngeal dysplasia: a systematic review. Accepted to Head and Neck. 2010.
53. Schaaij-Visser TB, Bremmer JF, Braakhuis BJ, Heck AJ, Slijper M, van der Waal I, et al. Evaluation of cornulin, keratin 4, keratin 13 expression and grade of dysplasia for predicting malignant progression of oral leukoplakia. Oral Oncol. 2010 Feb;46(2):123-7.
54. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). British journal of cancer. [10.1038/sj.bjc.6602678]. 2005;93(16106245):387-91. This paper suggests guidelines to enable more standardized and transparent reporting of biomarker studies.
55. Fleskens S, Takes R, Otte-H?̃?́ller I, Van Doesburg L, Smeets A, Speel E, et al. Simultaneous assessment of DNA ploidy and biomarker expression in paraffin-embedded tissue sections. Histopathology. [10.1111/j.1365-2559.2010.03599.x]. 2010;57 (20653778):14-26.
56. Epstein JB, Gorsky M, Fischer D, Gupta A, Epstein M, Elad S. A survey of the current approaches to diagnosis and management of oral premalignant lesions. Journal of the American Dental Association (1939). 2007;138(18056099):1555-62; quiz 614.
57. Marley JJ, Linden GJ, Cowan CG, Lamey PJ, Johnson NW, Warnakulasuriya KA, et al. A comparison of the management of potentially malignant oral mucosal lesions by oral medicine practitioners and oral & maxillofacial surgeons in the UK. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 1998;27(9831962):489-95. (Pubitemid 28514886)
58. Spielmann P, Palmer T, McClymont L. 15-Year review of laryngeal and oral dysplasias and progression to invasive carcinoma. European Archives of Oto-Rhino-Laryngology. [10.1007/s00405-009-1013-9]. 2010;267(19543904):423-7.
59. Mehanna H, Paleri V, Robson A, Wight R. Consensus statement on the management of Laryngeal Dysplasia. Clinical Otolaryngology. 2010;in print.